Global Nicotine Collaboration Pushes This Microcap Closer to Commercialization

Sponsored:

Tuesday, July 7, 2026

The global nicotine market is shifting as consumers increasingly look beyond cigarettes toward smoke-free formats that are more discreet, convenient, and compatible with modern lifestyles. Pouches have already proven the appetite for alternatives, but the next wave may come from delivery technologies that eliminate chewing, spitting, and disposal altogether.

Shares of Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) are moving higher today after the Canadian biotechnology company extended its collaboration with a global nicotine industry leader and opened a separate path toward commercializing its QuickStrip™ nicotine technology in Saudi Arabia.

Rapid Dose specializes in oral thin-film drug delivery. Its proprietary QuickStrip™ platform uses a fast-dissolving oral film capable of carrying active ingredients including nutraceuticals and pharmaceuticals, with its NicStrip™ product applying the technology to nicotine.

The company signed a memorandum of understanding with an unnamed global leader in the nicotine products industry, extending an existing collaboration around QuickStrip™ dissolvable oral nicotine strips. The MOU follows completion of a prior pre-commercialization development agreement and is designed to bridge the companies into the next stage of commercialization planning while continuing services and related fees. Over the first four to six weeks, the parties plan to jointly develop a formal program outlining short, mid, and long-term objectives, responsibilities, milestones, services, and payments needed to commercialize the products. That agreement is expected to open a final six-month window focused on launch milestones, including branding, regulatory affairs, technical validation, product benchmarking, commercial assessment, and launch readiness.

The MOU also carves out Saudi Arabia as a separate opportunity, allowing Rapid Dose to independently pursue commercialization in the Kingdom while the broader global collaboration continues. The company has begun discussions with prospective regional partners to establish a market for NicStrip™. It cited an estimated adult smoking population of roughly five million, modern pharmacy and retail infrastructure, and growing demand for smoke-free alternatives, and views the Kingdom as a potential gateway to expansion across the Gulf Cooperation Council region.

Unlike nicotine gums, lozenges, patches, or pouches, QuickStrip™ dissolves in the mouth with no chewing, spitting, or visible disposal. Management believes the discreet, portable format could differentiate the product in markets where convenience and privacy matter to consumers.

"The decision by a global industry leader to extend our collaboration demonstrates strong confidence in our proprietary oral thin-film technology and provides a clear pathway toward commercial readiness," said Jason Lewis, SVP of Rapid Dose Therapeutics.

In Tuesday morning action, shares of DOSE are ahead 18.2% to C$0.13, while RDTCF are flat at $0.09.

Sponsored: